

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5782

In Re Application Of: **Elisabettini et al.**


Serial No.
10/044,234

Filing Date
January 11, 2002

Examiner
Unknown

Group Art Unit
1616

Title: BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES



Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5782

In Re Application: **Elisabettni et al.**


Serial No.
10/044,234

Filing Date
January 11, 2002

Examiner
Unknown

Group Art Unit
1616

BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **02-1818** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited
03/29/2002 with the U.S. Postal Service
as first class mail under 37 C.F.R. 1.8 and is
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231

Signature of Person Mailing Correspondence

Robert J. Buccieri

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: **March 29, 2002**

Thomas C. Basso
Reg. No. 46,541
P.O. B x 1135
Chicag , IL 60690-1135
Phone: (312) 807-4204

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Elisabettni et al.
Appl. No.: 10/044,234
Filed: January 11, 2002
Title: BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES
Art Unit: 1616
Examiner: Unknown
Docket No.: DI-5782

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

OTHER DOCUMENTS

- Mehta et al., *Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients*, Kidney International, Vol. 38 (1990), pp. 976-981.
- van Bommel et al., *Continuous Renal Replacement Therapy for Critically Ill Patients: An Update*, Journal of Intensive Care Medicine, Vol. 9, No. 6, November-December 1994, pp. 265-280.
- S. Uthoff et al., *Improved Correction of Acidosis in Acute Renal Failure Using a Bicarbonate Buffered Substitution Solution*, Nephrology (1997), Suppl. 1, P1598.
- A. N. Thomas et al., *Comparison of lactate and bicarbonate buffered haemofiltration fluids: use in critically ill patients*, Nephrology Dialysis Transplantation, (1997), Vol. 12, pp. 1212-1217.
- Manns et al., *Continuous Renal Replacement Therapies: An Update*, American Journal of Kidney Diseases, Vol. 32, No. 2 (August) 1998; pp. 185-207.
- Feriani et al., *Acid-base balance and replacement solutions in continuous renal replacement therapies*, Kidney International, Vol. 53, Suppl. 66 (1998), pp. S-156-S-159.
- Heering et al., *The use of different buffers during continuous hemofiltration in critically ill patients with acute renal failure*, Intensive Care Medical (1999) Vol. 25, pp. 1244-1251.
- Zimmerman et al., *Continuous veno-venous haemodialysis with a novel bicarbonate dialysis solution: prospective cross-over comparison with a lactate buffered solution*, Nephrology Dialysis Transplantation, (1999) Vol. 14, pp. 2387-2391.


- Heering et al., *Acid-base balance and substitution fluid during continuous hemofiltration*, Kidney International, Vol. 56, Suppl. 72 (1999) pp. S-37-S-40.
- Lutkes et al., *Continuous venovenous hemodialysis treatment in critically ill patients after liver transplantation*, Kidney International, Vol. 56 Suppl. 72 (1999) pp. S-71-S-74.
- Kierdorf et al., *Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies*, Kidney International, Vol. 56, Suppl. 72 (1999) pp. S-32-S-36.
- Barenbrock et al., *Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients*, Kidney International, Vol. 58 (2000) pp. 1751-1757.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY



Thomas C. Basso
Reg. No. 46,541
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204